Mylan to Issue Refunds for 340B Overcharges

by Admin | November 7, 2012 2:48 pm

November 7, 2012—Drug manufacturer Mylan will soon be mailing refunds to 340B providers for overcharges on all products sold by its Dey Pharma subsidiary from late 1994 through late 2006, according to an announcement on the Office of Pharmacy Affairs (OPA) home page[1].

In its statement on the OPA Web site, Mylan said the need to provide refunds to 340B covered entities “arises from a recalculation of average manufacturer prices [AMPs] and best prices” reported by Dey Pharma to the Centers for Medicare and Medicaid Services (CMS) under the Medicaid rebate program. 

---

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[2].    Already registered? Click here to login[3]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

 

Source URL: https://340binformed.org/2012/11/mylan-to-issue-refunds-for-340b-overcharges/

---